March 10, 2020 10:17 AM EDTUpdated March 11, 02:33 PM

To arm the immune system for sustained attack against HIV, NIH scientists take to viral vectors

Natalie Grover

Reporter

While stem cell treatment for HIV — engineered to stop the virus from replicating within the body by replacing the patient’s own immune cells with donor …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

To arm the immune system for sustained attack against HIV, NIH scientists take to viral vectors

Natalie Grover

Reporter

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Bristol Myers sues the federal government over 340B, following other drugmakers

Novartis to cut 139 jobs in NJ as part of commercial refocus

To arm the im­mune sys­tem for sus­tained at­tack against HIV, NIH sci­en­tists take to vi­ral vec­tors

Natalie Grover

Reporter

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

To arm the immune system for sustained attack against HIV, NIH scientists take to viral vectors

Applied Therapeutics' rare disease drug gets a CRL

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Bristol Myers sues the federal government over 340B, following other drugmakers

Novartis to cut 139 jobs in NJ as part of commercial refocus